The article titled “Imatinib: A Breakthrough of Targeted Therapy in Cancer” [1] was found to contain material from previously published work, mainly in sections 3.1, 3.3, 3.4, 3.5, and 3.6. The articles are as follows:(i)S. A. Khan, “Targeted therapies for philadelphia chromosome-positive acute lymphoblastic leukemia,” School of Pharmacy, 37, 5 (Oncology suppl): 3–7, 2012 (https://www.uspharmacist.com/article/targeted-therapies-for-philadelphia-chromosome-positive-acute-lymphoblastic-leukemia) [2] (not cited).(ii)A. Olivieri, M. Cimminiello, P. Corradini, et al., “Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD,” Blood, 2013, doi: https://doi.org/10.1182/blood-2013-05-494278 (http://www.bloodjournal.org/content/122/25/4111) [3] (cited as reference 56).(iii)C. Ustun, D. L. DeRemer, and C. Akin, “Tyrosine kinase inhibitors in the treatment of systemic mastocytosis,” Leukemia Research, 2011, doi: https://doi.org/10.1016/j.leukres.2011.05.006 (https://www.lrjournal.com/article/S0145-2126(11)00223-2/fulltext) [4] (not cited).(iv)S. Verstovsek, “New Hematological Indications for Imatinib,” Hematological Cancer, 2007, doi: http://doi.org/10.17925/OHR.2007.00.2.36 (https://www.touchoncology.com/articles/new-hematological-indications-imatinib) [5] (not cited).(v)M. Breccia and G. Alimena, “Resistance to Imatinib in chronic myeloid leukemia and therapeutic approaches to circumvent the problem,” Cardiovascular and Hematological Disorders-Drug Targets, 2009, doi: https://doi.org/10.2174/187152909787581363 (http://www.eurekaselect.com/68887/article) [6] (not cited).
Corrigendum to “Imatinib: A Breakthrough of Targeted Therapy in Cancer”
References
N. Iqbal and N. Iqbal, “Imatinib: a breakthrough of targeted therapy in cancer,” Chemotherapy Research and Practice, vol. 2014, Article ID 357027, 9 pages, 2014.
View at: Publisher Site | Google ScholarS. A. Khan, “Targeted therapies for philadelphia chromosome-positive acute lymphoblastic leukemia,” School of Pharmacy, vol. 37, no. Oncology suppl, pp. 3–7, 2012.
View at: Google ScholarA. Olivieri, M. Cimminiello, P. Corradini et al., “Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD,” Blood, vol. 122, no. 25, pp. 4111–4118, 2013.
View at: Publisher Site | Google ScholarC. Ustun, D. L. DeRemer, and C. Akin, “Tyrosine kinase inhibitors in the treatment of systemic mastocytosis,” Leukemia Research, vol. 35, no. 9, pp. 1143–1152, 2011.
View at: Publisher Site | Google ScholarS. Verstovsek, “New hematological indications for Imatinib,” Oncology & Hematology Review (US), vol. 1, no. 2, pp. 36–39, 2007.
View at: Publisher Site | Google ScholarM. Breccia and G. Alimena, “Resistance to Imatinib in chronic myeloid leukemia and therapeutic approaches to circumvent the problem,” Cardiovascular & Hematological Disorders-Drug Targets, vol. 9, no. 1, pp. 21–28, 2009.
View at: Publisher Site | Google Scholar